Federal Agencies Secretly Test Anthropic's AI Despite Trump Administration Ban 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
Pentagon Taps Auto Giants to Supercharge U.S. Weapons Production 
Iran War Drives Asia's Plastic Crisis — and a Green Packaging Boom 
NiSource Signs Long-Term Energy Deals with Alphabet and Amazon to Power Indiana Data Centers 
SK Hynix Shares Hit Record High Amid AI Memory Demand Surge 
Japan Opens Arms Export Floodgates: New Policy Draws Global Defense Interest 
Goldman Sachs FICC Revenue Falls 10% Amid Iran War Market Volatility 
Tesla's Terafab: AI Chip Factory Eyes Taiwan's Semiconductor Talent 
Daikin Industries Stock Surges 14% After Elliott Investment Management Discloses Major Stake 
Federal Judge Dismisses DOJ Lawsuit Attempting to Block Hawaii's Climate Case Against Oil Giants 
Elon Musk's Terafab Foundry Courts Top Chipmaking Giants for AI Self-Sufficiency Push 
Uber Bets Big on Autonomous Vehicles with $10 Billion Commitment 
Japan to Subsidize Sony's Image Sensor Plant in Kumamoto with $380 Million 
CSN's Cement Unit Sale Could Exceed $2 Billion as Global Giants Circle 
Samsung Races to Deliver Next-Gen HBM4E Memory Samples to Nvidia 
CATL Stock Hits Record High After Q1 2025 Earnings Surge 
SAN DIEGO, May 31, 2017 -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration and fibrotic diseases, announced today that Charles Theuer, M.D., Ph.D., President and CEO, will present at the Jefferies 2017 Healthcare Conference at 4:00 pm EDT on Wednesday, June 7, 2017, in New York, NY.
To access a live webcast of the presentation, please visit the “Events and Presentation” section within the “Investors” section of the TRACON Pharmaceuticals website at www.traconpharma.com. A replay of the webcast will be available on the website for 60 days following the event.
About TRACON
TRACON develops targeted therapies for cancer, ophthalmic and fibrotic diseases. The Company’s clinical-stage pipeline includes: TRC105, an endoglin antibody that is being developed for the treatment of multiple cancers; DE-122, the ophthalmic formulation of TRC105 that is being developed in wet AMD through a collaboration with Santen Pharmaceutical Company Ltd.; TRC102, a small molecule that is being developed for the treatment of lung cancer and glioblastoma; and TRC253, a small molecule that is being developed for the treatment of prostate cancer. To learn more about TRACON and its product candidates, visit TRACON's website at www.traconpharma.com.
Company Contact: Casey Logan Chief Business Officer (858) 550‐0780 ext. 236 [email protected] Company Contact: Casey Logan Chief Business Officer (858) 550‐0780 ext. 236 [email protected]
